Document:

Exhibit 10.12

      

    

     

      

     

    
    DATED [●]

    

    

    

    

    

    

    

    

    (1) [●]

    

    

    

    

    

    

    (2) A.T. DEVELOPMENT SWITZERLAND SARL

    

    

    

    

    

    

    AND

    

    

    

    

    

    

    (3) ADC THERAPEUTICS SARL

    

    

    

    

    

    

    

    

    	 
	
            FORM OF PURCHASE AND SHAREHOLDERS AGREEMENT

          
	 

    

    

    
      
        

    

    
      
         TABLE OF CONTENTS

        

        

        

        
          	 	 	 Page
	 	 	 
	
                  1.

                	
                  DEFINITIONS AND INTERPRETATION

                	
                  1

                
	 	 	 
	
                  2.

                	
                  PURCHASE

                	
                  2

                
	 	 	 
	
                  3.

                	
                  COMPLETION

                	
                  2

                
	 	 	 
	
                  4.

                	
                  NOMINEE

                	
                  2

                
	 	 	 
	
                  5.

                	
                  DEALINGS IN SHARES

                	
                  3

                
	 	 	 
	
                  6.

                	
                  ADHERENCE

                	
                  3

                
	 	 	 
	
                  7.

                	
                  LEAVER PROVISIONS

                	
                  3

                
	 	 	 
	
                  8.

                	
                  ASSIGNMENT

                	
                  4

                
	 	 	 
	
                  9.

                	
                  THIRD PARTY RIGHTS

                	
                  4

                
	 	 	 
	
                  10.

                	
                  STATUS OF THIS AGREEMENT

                	
                  5

                
	 	 	 
	
                  11.

                	
                  ACKNOWLEDGMENT

                	
                  5

                
	 	 	 
	
                  12.

                	
                  SEVERANCE

                	
                  5

                
	 	 	 
	
                  13.

                	
                  VARIATION

                	
                  5

                
	 	 	 
	
                  14.

                	
                  COSTS

                	
                  6

                
	 	 	 
	
                  15.

                	
                  WHOLE AGREEMENT

                	
                  6

                
	 	 	 
	
                  16.

                	
                  FURTHER ASSURANCE

                	
                  6

                
	 	 	 
	
                  17.

                	
                  COUNTERPARTS

                	
                  6

                
	 	 	 
	
                  18.

                	
                  GOVERNING LAW AND JURISDICTION

                	
                  6

                

        

         

        

        

        

      

    

    
      
        

    

    

    

    THIS AGREEMENT is made on [●]

    

    

    BETWEEN

    

    

    
      
        	(1)	
                [●] (the “Shareholder”);

              

      

    

    

    

    
      
        	(2)	
                A.T. DEVELOPMENT SWITZERLAND SARL a company registered in Switzerland with its registered office at Rue Saint Pierre 2, Lausanne, 1003, Switzerland (“ATDS”);

                  and 

                  

                  

                  solely for the purpose of gaining the benefit of the clauses of this Agreement in which it has an interest,

              

      

    

    

    

    
      
        	(3)	
                ADC THERAPEUTICS SARL a company registered in Switzerland with its registered office at Rue Saint Pierre 2, Lausanne, 1003, Switzerland (“Company”).

              

      

    

    

    

    
      
        	1.	
                DEFINITIONS AND INTERPRETATION

              

      

    

    

    

    
      
        	1.1	
                In this agreement unless the context otherwise requires:

                 

                

              

      

    

    	 	
            Anniversary Date

          	
            means [●]

          
	 	 	 
	 	
            Articles

          	
            the articles of association of the Company as amended, modified, supplemented or restated from time to time;

          
	 	 	 
	 	
            Bad Leaver

          	
            means a Leaver who is not a Good Leaver;

          
	 	 	 
	 	
            Completion

          	
            completion of this agreement in accordance with clause 2 and clause 3;

          
	 	 	 
	 	
            Employment

          	
            means, for the purposes of this agreement, acting as an employee, officer, manager, director, advisor, consultant, partner, agent, representative or the like to the Company or any member of
              the Company’s group;

          
	 	 	 
	 	
            Good Leaver

          	
            means a person who is a Leaver (i) as a result of his death or serious ill health;  or (ii) who has otherwise been determined by the Company’s board of directors acting reasonably to be a
              Good Leaver;

          
	 	 	 
	 	
            Leaver

          	
            means an individual who was previously in the Employment of the Company or any member of the Company’s group and who ceases to be in such Employment;

          
	 	 	 
	 	
            Parties

          	
            the parties to this agreement; and

          
	 	 	 
	 	
            Promissory Note

          	
            a promissory note from the Shareholder to ATDS substantially in the form attached at Schedule A.

          

    

    

    
      
        

    

    
      
        	1.2	
                In this agreement unless the context otherwise requires:

              

      

    

    

    

    
      
        	

              	1.2.1	
                a reference to writing or written includes faxes and email;

              

      

    

    

    

    
      
        	

              	1.2.2	
                any reference to the singular includes a reference to the plural and vice versa; and any reference to the masculine includes a reference to the feminine and vice versa; and

              

      

    

    

    

    
      
        	

              	1.2.3	
                references to times of day are, unless the context requires otherwise, to London time and references to a date are to a period of 24 hours running from midnight on the previous day.

              

      

    

    

    

    
      
        	

              	1.2.4	
                headings and titles are used for ease of reference only and do not affect the interpretation of this agreement.

              

      

    

    

    

    
      
        	2.	
                PURCHASE

              

      

    

    

    

    
      
        	2.1	
                ATDS hereby agrees to sell and the Shareholder hereby agrees to purchase [●] Class A shares in the capital of the Company (the “Shares”) subject to the terms of this agreement.  The
                  consideration for such subscription shall be satisfied by the payment of the sum of [●] (the “Purchase Price”) in accordance with clause 3.2.

              

      

    

    

    

    
      
        	2.2	
                The Shares shall be sold with full title guarantee free from all encumbrances and shall rank in full for all dividends or other distributions declared, made or paid in respect of ordinary shares on or after Completion, and shall have
                  the rights, preferences and priorities as set forth in the Articles.

              

      

    

    

    

    
      
        	2.3	
                The Parties acknowledge that the Company is not party to, and has no interest in, the sale and purchase of the Shares and is entering into this Agreement solely for the purposes of safeguarding the interests of the Company and the
                  rights of other shareholders in the Company by ensuring that the Shareholder is subject inter alia to the Leaver provisions in clause 7 of this agreement.

              

      

    

    

    

    
      
        	3.	
                COMPLETION

              

      

    

    

    

    
      
        	3.1	
                This agreement shall be completed at the offices of the Company’s legal counsel on the Completion Date (or at such other place or on such other date as the Parties shall agree).

              

      

    

    

    

    
      
        	3.2	
                On the Completion Date the Shareholder shall deliver, or procure the delivery, to the Company and/or ATDS as the case may be:

              

      

    

    

    

    
      
        	

              	3.2.1	
                the sum of CHF 100.00 per Share in cash representing the nominal value of the Shares;

              

      

    

    

    

    
      
        	

              	3.2.2	
                an executed counterpart of the Promissory Note for the balance of the Purchase Price.

              

      

    

    

    

    
      
        	3.3	
                On the Completion Date ATDS shall procure the delivery to the Shareholder of an internal capitalisation table of the Company evidencing the Shareholder’s beneficial interest in the Shares.

              

      

    

    

    

    
      
        	4.	
                NOMINEE

              

      

    

    

    

    
      
        	4.1	
                The Parties acknowledge that, as a matter of Swiss law the Company may not issue fractional interests in its shares. Therefore, the Shareholder acknowledges and agrees that ATDS shall continue to hold the legal interest in the Shares
                  as nominee for the Shareholder. ATDS shall act in its name for the account of the Shareholder and at the risk of the Shareholder.

              

      

    

    

    

    
      
        

    

    
      
        	4.2	
                The Shareholder irrevocably instructs and authorises ATDS to take all actions in respect of the Shares as ATDS may see fit including, without limitation:

              

      

    

    

    

    
      
        	

              	4.2.1	
                to receive notice of and to attend, take part and vote in all meetings of the Company and/or any relevant class meetings of its shareholders and sign all consents to short notice, proxies and other instruments (including without
                  limitation, proposed resolutions) for the purpose of such meetings;

              

      

    

    

    

    
      
        	

              	4.2.2	
                to pass any resolutions and/or to sign written resolutions of the shareholders or the holders of any class of shares of the Company;

              

      

    

    

    

    
      
        	

              	4.2.3	
                to give a good receipt for any dividend or other distribution made in respect of our shareholding; and

              

      

    

    

    

    
      
        	

              	4.2.4	
                to exercise all other rights and privileges and perform all duties which attach to our shares.

              

      

    

    

    

    
      
        	4.3	
                The Shareholder undertakes to ratify whatever ATDS may lawfully do or purport to do or cause to be done by virtue of the powers granted by this clause 4.

              

      

    

    

    

    
      
        	4.4	
                ATDS undertakes to deliver to the Shareholder copies of any and all Company communications within a reasonable period following receipt by ATDS of the same.

              

      

    

    

    

    
      
        	5.	
                DEALINGS IN SHARES

              

      

    

    

    

    

    	

          	
            The Shareholder undertakes to each of the Company and ATDS that he will not, at any time, transfer, dispose, assign, grant security over, pledge or otherwise deal in or grant any interest over any interest in the Shares to any person
              without the prior consent in writing of ATDS or the Company.

          

    

    

    
      
        	6.	
                ADHERENCE

              

      

    

    

    

    
      	

            	
              The Shareholder undertakes to the Company (for itself and on behalf of each other party to the Shareholders’ Agreement) that he will, with effect from the date hereof assume, perform and comply with each of the obligations as a
                Shareholder under the Shareholders’ Agreement as if he had been a party to the Shareholders’ Agreement at the date of its execution.

            

    

    

    

    
      
        	7.	
                LEAVER PROVISIONS

              

      

    

    

    

    
      
        	7.1	
                If the Shareholder’s Employment with the Company or any member of the Company’s group terminates for any reason, ATDS, the Company (or its designee) shall have the right, but not the obligation, to repurchase all or any portion of the
                  Shareholder’s Shares at the applicable repurchase price, within thirty (30) days of the event, as follows:

              

      

    

    

    

    
      
        	

              	7.1.1	
                Good Leaver. If the Shareholder’s Employment is terminated and the Shareholder is a Good Leaver, ATDS, the Company (or its designee) shall have the option, but not the obligation, to repurchase such portion of the Shareholder’s
                  Shares as is determined in accordance with the table below at a price per Share equal to the purchase price of such Share (calculated by dividing the Purchase Price for all Shares by the number of Shares being acquired pursuant to this
                  clause) as of the date such Shareholder is provided with a written notice requiring the repurchase of his Shares. Such consideration may at the election of the Company be satisfied by a waiver of all or part of the Shareholder’s
                  outstanding obligations under the Promissory Note.

              

      

    

    

    

    
      
        

    

    

    

    	
            Date on which the Shareholder’s Employment terminates if he is a Good Leaver

             

            

          	
            % of Shareholder’s Shares ATDS, the Company (or its designee) may repurchase

          
	
            On or before the first anniversary of the Anniversary Date

             

            

          	
            100%

          
	
            After the first anniversary of the Anniversary Date but on or before the second anniversary of the Anniversary Date

             

            

          	
            75%

          
	
            After the second anniversary of the Anniversary Date but on or before the third anniversary of the Anniversary Date

             

            

          	
            50%

          
	
            After the third anniversary of the Anniversary Date but on or before the fourth anniversary of the Anniversary Date

             

            

          	
            25%

          
	
            After the fourth anniversary of the Anniversary Date

             

            

          	
            0%

          

     

    

    

    

    
      
        	

              	7.1.2	
                Bad Leaver. If the Shareholder’s Employment is terminated and the Shareholder is a Bad Leaver, ATDS, the Company (or its designee) shall have the option, but not the obligation, to repurchase all or any portion of such
                  Shareholder’s Shares at a price per Share equal to the lower of (i) the Purchase Price of such Shares; and (ii) the amount understanding under the Promissory Note at the time such shareholder’s employment is terminated. Such consideration
                  may at the election of the Company be satisfied by a waiver of all or part of the Shareholder’s outstanding obligations under the Promissory Note.

              

      

    

    

    

    
      
        	7.2	
                The Company shall not terminate the Employment of the Shareholder solely for the purposes of causing the Shareholder not to enjoy the economic benefits of this Purchase and Shareholder Agreement.

              

      

    

    

    

    
      
        	8.	
                ASSIGNMENT

              

      

    

    

    

    
      	

            	
              The Shareholder may not assign its rights under this agreement without the prior written consent of ATDS.

            

    

    

    

    
      
        	9.	
                THIRD PARTY RIGHTS

              

      

    

    

    

    
      	

            	
              This agreement does not confer any rights on any person that is not a party to this agreement pursuant to the Contracts (Rights of Third Parties) Act 1999.

            

    

    

    

    
      
        

    

    

    

    
      
        	10.	
                STATUS OF THIS AGREEMENT

              

      

    

    

    

    
      
        	10.1	
                Each of the Parties shall use its respective best endeavours to procure (so far as is possible) that, at all times during the term of this agreement, the provisions of this agreement are promptly observed and given full force and
                  effect according to its spirit and intention.

              

      

    

    

    

    
      
        	10.2	
                If, at any time, any provisions of the Articles conflict with any provision of this agreement, ATDS and the Company shall, so far as they are each able, take such steps as are necessary to ensure that the provisions of this agreement
                  shall prevail and that such modifications as are necessary are made to the Articles.

              

      

    

    

    

    
      
        	11.	
                ACKNOWLEDGMENT

              

      

    

    

    

    
      
        	11.1	
                Each Party acknowledges that damages may not be an adequate remedy for any breach of the obligations of that Party in this Agreement and that any other Party may be entitled (in addition to damages) to the remedies of injunction,
                  specific performance, and other equitable remedy for any threatened or actual breach of any such obligations.

              

      

    

    

    

    
      
        	11.2	
                The Shareholder confirms to ATDS and the Company that, for the purposes of entering into the transactions contemplated by this agreement he has (having taken taken all applicable professional advice) entered into this agreement
                  entirely on the basis of his own assessment of the risks and effect of doing so.

              

      

    

    

    

    
      
        	12.	
                SEVERANCE

              

      

    

    

    

    
      
        	12.1	
                If any provision of this agreement (or part of a provision) is found by any court or administrative body of competent jurisdiction to be invalid, unenforceable or illegal, the other provisions shall remain in force.

              

      

    

    

    

    
      
        	12.2	
                If any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted or modified, that provision shall apply with whatever modification is necessary to give effect to the commercial
                  intention of the Parties.

              

      

    

    

    

    
      
        	13.	
                VARIATION

              

      

    

    

    

    
      
        	13.1	
                A variation of this agreement shall be in writing and signed by or on behalf of each Party.

              

      

    

    

    

    
      
        	13.2	
                Any waiver of any right under this agreement is only effective if it is in writing and signed by the waiving or consenting Party and it applies only in the circumstances for which it is given and shall not prevent the Party who has
                  given the waiver or consent from subsequently relying on the provision it has waived.

              

      

    

    

    

    
      
        	13.3	
                No single or partial exercise of any right or remedy under this agreement shall preclude or restrict the further exercise of any such right or remedy.

              

      

    

    

    

    
      
        	13.4	
                Unless specifically provided otherwise, rights arising under this agreement are cumulative and do not exclude rights provided by law.

              

      

    

    

    

    
      
        	13.5	
                Save as specified in this agreement, no failure on the part of any Party to exercise or no delay in exercising any right or remedy provided under this agreement or by law constitutes a waiver of such right or remedy or shall prevent
                  any future exercise in whole or in part of any such right or remedy.

              

      

    

    
      
        

    

    

    

    
      
        	14.	
                COSTS

              

      

    

    

    

    
      	

            	
              Unless otherwise provided, all costs and expenses in connection with the negotiation, preparation, execution and performance of this agreement, and any documents referred to in it,
                shall be borne by the Party that incurred the costs.

            

    

    

    

    
      
        	15.	
                WHOLE AGREEMENT

              

      

    

    

    

    
      
        	15.1	
                This agreement, and any documents referred to in it constitute the whole agreement between the Parties and supersede any previous arrangement, understanding or agreement between them relating to the subject matter they cover.

              

      

    

    

    

    
      
        	15.2	
                Nothing in this clause 15 operates to limit or exclude any liability for fraud.

              

      

    

    

    

    
      
        	16.	
                FURTHER ASSURANCE

              

      

    

    

    

    
      	

            	
              
                Each Party shall promptly execute and deliver all such documents, and do all such things, as any other Party may from time to time reasonably require for the
                  purpose of giving full force and effect to the provisions of this agreement.

              

            

    

    

    

    
      
        	17.	
                COUNTERPARTS

              

      

    

    

    

    
      	

            	
              
                This agreement may be executed in separate counterparts (including by facsimile or other electronic transmission), each of which is an
                  original and which, when executed and delivered, shall be an original and which together shall have the same effect as if each Party had executed and delivered the same document.

              

            

    

    

    

    
      
        	18.	
                GOVERNING LAW AND JURISDICTION

              

      

    

    

    

    
      
        	18.1	
                This agreement and any dispute or claim arising out of or in connection with it or its subject matter (including non-contractual disputes or claims) shall be governed by and construed in accordance with the law of England and Wales.

              

      

    

    

    

    
      
        	18.2	
                The Parties agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this agreement or its subject matter (including non-contractual disputes
                  or claims).

              

      

    

    
      
        

    

    

    

    SCHEDULE A

    

    

    Promissory Note

    

    

    	
            Amount:

          	
            [●] (the “Facility”)

          
	 	 
	
            Number of shares to be Purchased:

          	
            [●] (the “Shares”)

          
	 	 
	
            Interest Rate:

          	
            [●]%

          
	 	 
	
            Term:

          	
            [●] years

          

    

    

    Date: [●]

    

    

    Dear [●],

    

    

    We are pleased to make available to you the Facility on the terms and conditions set out in this letter. By signing and returning a signed copy of this letter you agree to be bound by and abide by
      its terms.

    

    

    This Facility and its availability for drawing by you is subject to the receipt by us of an executed copy of the Purchase and Shareholder Agreement in respect of the Shares purchased by you
      utilising this Facility.

    

    

    Words and expressions used in this letter but not defined herein shall have the meanings given to them in the Company’s articles of association.

    

    

    The Facility is made available to you on the following terms:-

    

    

    
      
        	1.	
                We hereby loan the Facility to you to be repaid along with accrued interest (if any) on the earlier of:

              

      

    

    

    

    
      
        	1.1	
                the date [●] ([●]) years from the date hereof;

              

      

    

    

    

    
      
        	1.2	
                the occurrence of a Repayment Event as defined in paragraph 3 below.

              

      

    

    

    

    
      
        	2.	
                The Facility may only be used for the purchase of the Shares (“Authorised Purpose”).

              

      

    

    
      
        

    

    

    

    
      
        	3.	
                “Repayment Event” means any of:

              

      

    

    

    

    
      
        	3.1	
                you are a Leaver and ATDS or the Company (or its designee) elects to repurchase your Shares in accordance with the terms of the Purchase and Shareholder Agreement entered into between you, ATDS and the Company;

              

      

    

    

    

    
      
        	3.2	
                the Company is the subject of a change of control or a sale of all or substantially all of its assets; or

              

      

    

    

    

    
      
        	3.3	
                you deliver the Shares back to ATDS or the Company.

              

      

    

    

    

    
      
        	4.	
                The Facility will be immediately repayable and you hereby undertake to repay, and to take all necessary action to repay, the Facility in full, or any part of it that has not been repaid, on the occurrence of a Repayment Event.

              

      

    

    

    

    
      
        	5.	
                You may repay the Facility, or any part of it, early along with accrued interest but may not re-borrow any amount so repaid.

              

      

    

    

    

    
      
        	6.	
                The principal amount of the Facility outstanding from time to time will be interest free

              

      

    

    

    

    
      
        	7.	
                You will make all payments under or in respect of this Facility without set-off or counterclaim and free and clear of any withholding or deduction for or on account of tax, save as may be required by law.

              

      

    

    

    

    
      
        	8.	
                You will pay, on demand and on a full indemnity basis, all costs and expenses (including VAT) which we may from time to time incur in connection with any breach by you of your obligations under this letter and/or in relation to the
                  Facility.

              

      

    

    

    

    
      
        	9.	
                Any demand or notice in respect of this letter and/or the Facility will be in writing and (without prejudice to any other effective means of serving it) may be served on you personally or by post to your residential address as it
                  appears at the head of this letter.

              

      

    

    

    

    
      
        	10.	
                Time shall be of the essence in respect of your obligations under or in respect of this Facility but no failure by us to exercise or delay by us in exercising any right or remedy under or in respect of this Facility shall operate as a
                  waiver of it, nor shall any single partial or defective exercise by us of any such right or remedy preclude any other or further exercise of that or any other right or remedy.

              

      

    

    

    

    
      
        	11.	
                You may not assign or transfer any of your rights or obligations under this letter agreement without our prior written consent.

              

      

    

    

    

    
      
        	12.	
                This letter is an agreement governed by English law.

              

      

    

    

    

    I hereby accept and agree to be bound by the terms and conditions set out in the letter of which this is a copy

    

    

    
      	 	 

    

    Shareholder

    

    

    

    

    This agreement has been executed as a DEED on the date stated at the beginning of it.Exhibit 10.13

   

  THE ADC THERAPEUTICS INCENTIVE PLAN DATED MAY 1, 2014

   

  AMENDED AND RESTATED AS OF 1st DAY OF OCTOBER, 2015

   

  RULES

   

  Adopted as of the 1st day of October, 2015 by:

   

  ADC Therapeutics Sàrl (upon conversion on October 13, 2015: ADC Therapeutics SA)

  ADC Therapeutics (UK) Limited

  ADC Therapeutics America, Inc.

  
    
      
 

  

   

  CONTENTS

   

  	WHEREAS	1
	 	 
	1.	DEFINITIONS AND INTERPRETATION	2
	 	 	 
	2.	GRANT OF AWARDS	5
	 	 	 
	3.	DOCUMENTATION OF AWARDS	6
	 	 	 
	4.	NO DEALING IN AWARDS	6
	 	 	 
	5.	PAYMENT AND LAPSE OF AWARDS	7
	 	 	 
	6.	LIQUIDITY EVENT	7
	 	 	 
	7.	VARIATION OF CAPITAL	8
	 	 	 
	8.	PARTICIPATION SEPARATE FROM EMPLOYMENT OR SERVICE	9
	 	 	 
	9.	TAX AND SOCIAL SECURITY	9
	 	 	 
	10.	ADMINISTRATION, AMENDMENT AND TERMINATION	10

   

  
    
      
 

  

  THE ADC THERAPEUTICS INCENTIVE PLAN

   

  RULES

   

  WHEREAS

   

  	 	A)	On May 1, 2014, A.T. Development Switzerland Sàrl, ADC Therapeutics Services (UK) Limited and the Company’s Bermuda branch
          entered into this Plan.

   

  	 	B)	Further to an internal reorganization of the Company’s activities, the Participants to the Plan formerly employed by A.T. Development Switzerland Sàrl and ADC Therapeutics
          Services (UK) Limited were transferred to the Company and ADC Therapeutics (UK) Limited, respectively, and the Participants having been granted an Award by the Company’s Bermuda branch were transferred from C.T. Development America, Inc. to ADC
          Therapeutics America, Inc.

   

  	 	C)	The Company, ADC Therapeutics (UK) Limited and ADC Therapeutics America, Inc. wish to ensure continuity of the Awards to the benefit of the Participants as of the Date of
          Grant and amend the Plan as further stated herein.

   

  	 	D)	The purpose of this Plan is to incentivize selected employees or service providers of the Company, ADC Therapeutics (UK) Limited and ADC Therapeutics America, Inc. to accept
          employment or service, foster retention of such employees or service providers and encourage them to contribute maximum efforts to the success of the Company’s and its affiliates’ business.

   

  	 	E)	Pursuant to an amended and restated shareholders’ agreement dated as of August 10, 2015, the shareholders of the Company approved the implementation of an incentive plan
          comprised of up to 12% of the Company’s issued share capital at any time.

   

  	 	F)	Within the share capital limitation set forth above, this Plan will be implemented individually by each of the Company, ADC Therapeutics (UK) Limited and ADC Therapeutics
          America, Inc. to fulfil their respective obligations to employees and/or service providers designated by them from time to time to receive Awards under this Plan.

   

  	 	G)	Each Administrator may from time to time consult with the board of directors of the Company and, where necessary for consistency or compliance with the governance obligations
          of the Company pursuant to its amended and restated shareholders agreement or other organizational documents, seek the prior consent of the board of directors of the Company.

   

   

  
 1
  
    
      
 

  

  	 	H)	This Plan shall apply to (i) any Awards granted under this Plan prior to October 1, 2015, and (ii) any Awards to be granted as of October 1, 2015. For the avoidance of doubt,
          it is further understood that:

   

  		-	the Awards granted by A.T. Development Switzerland Sàrl under this Plan before October 1, 2015 shall be assigned to and assumed by the Company;

   

  		-	the Awards granted by ADC Therapeutics Services (UK) Limited under this Plan before October 1, 2015 shall be assigned to and assumed by ADC Therapeutics (UK) Limited; and

   

  		-	Awards granted by the Company’s Bermuda branch to its Service Providers under this Plan before October 1, 2015 shall continue with the Company under the terms of such Awards.

   

  	 	1.	DEFINITIONS AND INTERPRETATION

   

  		1.1	In this Plan (unless the context otherwise requires):

   

  “Administrator” means, unless otherwise specified in the applicable Country Annex, the Service Recipient of the Participant;

   

  “Asset Sale” means the sale by the Company of all or substantially all (but, for the avoidance of doubt, no less than 90% of the fair market value)
    of its business and assets to a person who is not a Member of the Group;

   

  “Award” means, unless otherwise specified in the applicable Country Annex, a right (for the time being subsisting) which following a Liquidity Event
    will entitle the holder to receive such number of Shares as indicated in the Award Letter or the Cashout Amount;

   

  “Award Letter” means the letter issued by the Administrator with the contents set forth in Rule 3.

   

  “Cashout Amount” shall mean an amount payable to a Participant in relation to an Award in accordance with Rule 6;

   

   

  
 2
  
    
      
 

  

  “Cause” means a Participant’s (i) material breach of any agreement (including any agreement containing restrictive covenants) entered into with the
    Company or the Service Recipient (or any affiliate thereof, as applicable), (ii) misappropriation of the Company’s property or of the Service Recipient’s property, fraud, embezzlement, breach of a fiduciary
    duty, offering or acceptance of any bribe or other unlawful inducement, other acts of dishonesty against the Company or the Service Recipient (or any affiliate thereof), (iii) commission of, or plea of guilty or no contest to, any felony or any crime
    involving moral turpitude, (iv) material violation of the Company’s or the Service Recipient’s code of conduct or ethics, or applicable law that results or could reasonably be expected to result in harm to the Company or the Service Recipient (or any
    affiliate thereof); (v) failure to follow the lawful directives reasonably set forth by the Company or the Service Recipient; (vi) gross negligence, wilful misconduct or disloyalty in the performance (or non-performance) of his duties and
    responsibilities to the Company or the Service Recipient (and any affiliate thereof, as applicable), and (vii) any act amounting to gross misconduct in relation to the Participant’s employment or service relationship;

   

  “Closing Value” means the value of a Share as determined by the Administrator by reference to the Liquidity Event which has given rise to
    exercisability of an Award (for the avoidance of doubt, the value of a Share for this purpose will be adjusted for any transaction costs incurred in connection with a Liquidity Event);

   

  “Company” means ADC Therapeutics Sàrl or, as of October 13, 2015, ADC Therapeutics SA (or its successor);

   

  “Country Annex” means each Annex appended to this Plan, as amended from time to time, the terms of which form a part of the Plan and supersede any
    contrary provision in the Plan with respect to the applicable Participant;

   

  “Date of Grant” means the date on which an Award is granted under Rule 2 as further stated in the Award Letter;

   

  “Fund” means Auven Therapeutics Holdings L.P.;

   

  “Group” means the Company and any other company in which the Fund holds a direct or indirect controlling interest now and in the future, and “Member

      of the Group” shall be construed accordingly;

   

   

  
 3
  
    
      
 

  

  “IPO” means an initial public offering raising at least US$60 million by means of listing and admission to trading on an internationally recognized
    stock exchange;

   

  “Liquidity Event” means the first to occur of a Sale, a Merger, an Asset Sale and an IPO;

   

  “Merger” means the merger of the Company with another entity, following the completion of which less than 50 percent of the share capital (by votes
    and value) in the merged, continuing or successor entity is owned directly or indirectly by the Fund;

   

  “Notional Share” means a Share that is notionally (rather than actually) the subject of an Award;

   

  “Participant” means an individual selected by the Administrator pursuant to Rule 3 and who holds an Award, or (where the context admits) his
    personal representatives;

   

  “Personal Data” means any personal data that could identify the Participant, including details of the Award itself;

   

  “Plan” means this Plan constituted by the Rules and the Country Annexes;

   

  “Relevant Liability” means, in relation to any Cashout Amount or other settlement of an Award, an amount equal to any sums which the Service
    Recipient or any other Member of the Group are be obliged to deduct by law including (without limitation) the amount of income tax and social security (including national insurance) contributions for which such company has or is required to account to
    the taxation authorities in any jurisdiction as a consequence of a payment to the Participant of the Cashout Amount or other settlement of an Award;

   

  “Rules” means these rules as from time to time amended;

   

  “Sale” means a person or group of persons acting in concert (including AstraZeneca UK Limited, any affiliate thereof or any company it controls, but
    excluding the Fund or any Member of the Group) obtains more than 50% of the Shares;

   

  “Service Recipient” means, as applicable, the Company, ADC Therapeutics (UK) Limited or ADC Therapeutics
    America, Inc., each in its capacity as the entity by which the Participant is employed or, in case of a service or consulting agreement, to which a Participant provides direct services;

   

   

  
 4
  
    
      
 

  

  “Share” means a common Class A share with a par value CHF 100 of the Company (or its successor);

   

  “Strike Price” means the value per Share as reasonably determined by the Administrator on the Date of Grant and as indicated in the Award Letter;

   

  “Vested” shall mean, in relation to an Award, that one or more tranches thereof has become vested according to the vesting schedule specified in
    Rule 3.3, and “Vesting” shall be construed accordingly.

   

  “Vested Award” means an Award that has Vested.

   

  		1.2	Words denoting the singular shall include the plural and vice versa.

   

  		1.3	Words denoting the masculine gender shall include the feminine gender.

   

  		1.4	References in these Rules to a rule, clause, sub-clause, paragraph or subparagraph are, unless otherwise stated, references to a rule, clause, sub-clause, paragraph or
          subparagraph of these Rules.

   

  		1.5	Rule headings are inserted for convenience only and are to be ignored in construing these Rules.

   

  		1.6	References in this Plan to any statute, regulation or enactment shall be deemed to include references to such statute, regulation or enactment as extended, re-enacted or
          amended.

   

  		1.7	Unless me Administrator otherwise determines, all sums shall be calculated and paid in US dollars.

   

  	 	2.	GRANT OF AWARDS

   

  The Administrator may by resolution grant Awards to one or more employees or service providers selected by the Administrator in its discretion, provided
    that:

   

  		2.1	no employee or service provider shall be entitled as of right to the grant of an Award;

   

  		2.2	no Award may be granted under this Plan after the tenth anniversary of the date of the adoption of the Plan by the Administrator; and

   

   

  
 5
  
    
      
 

  

  		2.3	the total number of Notional Shares or Shares, as applicable, to which all Awards refer shall not, at any time, exceed 12% of the Company’s issued share capital at any time.

   

  For the avoidance of doubt, Rule 2.3 above may only be amended by the board of directors of the Company.

   

  	 	3.	DOCUMENTATION OF AWARDS

   

  As soon as reasonably practicable after each Award is granted, the Administrator shall issue to each Participant an Award Letter, which shall specify:

   

  		3.1	the number of Notional Shares or Shares, as applicable, to which the Award relates;

   

  		3.2	the Date of Grant;

   

  		3.3	the vesting schedule for the Award, which shall unless otherwise determined by the Administrator in the Award Letter be as follows: 25% of the Notional Shares or Shares, as
          applicable, subject to an Award, shall Vest on each of the first, second, third and fourth anniversaries of the Date of Grant, in each case subject to Rule 5.2;

   

  		3.4	the Strike Price; and

   

  		3.5	such other terms and conditions as the Administrator shall determine (including terms and conditions to address any local legal and tax considerations).

   

  	 	4.	NO DEALING IN AWARDS

   

  Except as otherwise specifically provided in an Award Letter or as agreed subsequently, an Award shall be personal to the Participant and may not be
    transferred, assigned, charged, pledged or otherwise disposed of or dealt with, other than Awards which may be transferred by will or the laws of descent and distribution or under matrimonial laws. Any purported transfer, assignment, charge, pledge or
    other disposal or dealing with the Award shall cause the Award to lapse forthwith.

   

   

  
 6
  
    
      
 

  

  	 	5.	PAYMENT AND LAPSE OF AWARDS

   

  		5.1	Except as provided in the Country Annexes, an Award shall be settled and paid out only in accordance with Rule 6.

   

  		5.2	Where a Participant ceases to be an employee or service provider at any time:

   

  		5.2.1	by reason of termination for Cause, all Awards held by him (whether or not Vested) shall lapse forthwith without consideration therefor,

   

  		5.2.2	for any other reason, any Awards shall to the extent not already Vested lapse forthwith, without consideration therefor, while the Vested proportion shall
          continue in effect subject to these Rules, and shall be settled and paid on a Liquidity Event in accordance with Rule 6.

   

  		5.3	Where an Award continues to be in effect under Rule 5.2.2, an Award shall lapse and cease to be exercisable forthwith, without consideration therefor, if
          the Administrator reasonably determines that the Participant is in material breach of the terms of any settlement agreement relating to the termination of his employment or any other agreement with any Service Recipient (or any affiliate
          thereof), or has otherwise breached express or implied duties of confidentiality owed to the Company (or any of its affiliates) or the Service Recipient.

   

  		5.4	An Award shall automatically lapse, without consideration therefor, upon the earliest occurrence of any of the following events:

   

  		5.4.1	the tenth anniversary of the Date of Grant;

   

  		5.4.2	the Cashout Amount determined under Rule 6.2 being negative.

   

  	 	6.	LIQUIDITY EVENT

   

  		6.1	In the event of a Liquidity Event, any non-Vested Awards (other than those held by Participants who have ceased to be employees or service providers prior
          to the date of the Liquidity Event) shall automatically Vest in full.

  

   

  
 7
  
    
      
 

  

  
    	
            

            

          	
            6.2

          	
            Subject to Rules 6.3 and 6.4 and the Country Annexes, within 30 days following the Liquidity Event, each Participant shall be entitled to
              be paid by the Service Recipient a Cashout Amount calculated as follows:

          

  

  

  

  Cashout Amount = Z x (Closing Value less Strike Price)

   

   

  where Z is the number of Notional Shares or Shares in relation to which the Award has Vested. Any Relevant Liabilities arising thereon shall be
    deducted prior to payment.

   

  		6.3	Where the Liquidity Event takes the form of an IPO, the Administrator may in its discretion determine that Awards or parts thereof shall following Vesting
          be satisfied by transferring or procuring the issue to the Participant of Shares (or, if applicable, common shares of the public company that is the successor to the Company) with a fair market value equivalent to the Cashout Amount, less any Relevant Liabilities, provided that such Shares (or, if applicable, such common shares of the public company that is the successor to the Company) may be subject to limitations and transfer
          restrictions as the Administrator may in its discretion determine. In connection with an IPO, the Administrator may also determine to continue the Awards on such terms and conditions as it reasonably determines and in a manner consistent with
          applicable law.

   

  		6.4	Where the consideration on a Liquidity Event is deferred or contingent (which shall include an IPO where only
          part of the Fund’s holding is disposed of), the Administrator may in its discretion apply either or both of the following methods of payment:

   

  		6.4.1	determine a value of the Company based on the implied value of such deferred and/or contingent consideration, and make payments immediately on the basis that such value is
          included in the Closing Value for the purposes of Rule 6.2; or

   

  		6.4.2	make an initial payment under Rule 6.2 based on sums initially paid, followed by additional payments in the event that the deferred and/or contingent consideration is
          subsequently paid.

   

  	 	7.	VARIATION OF CAPITAL

   

  		7.1	In the event of any variation of the share capital of the Company (whenever effected) by way of capital increases or reductions, or share splits, payment of a special or
          extraordinary dividend, or otherwise, by the Company, the Strike Price and the number of Notional Shares or Shares, as applicable, in respect of which any Award granted under the Plan shall Vest may be adjusted by the Administrator in such manner
          as it sees fit.

   

   

  
 8
  
    
      
 

  

  		7.2	In the event of a group reorganization (including, without limitation, the formation of a new parent company), the Administrator may determine that the Notional Shares or
          Shares, as applicable, in which any Award granted under the Plan shall Vest, shall relate to the same or an adjusted number of shares of another company, provided that such shares have substantially an equivalent fair market value.

   

  		7.3	As soon as reasonably practicable after making any adjustment under Rules 7.1 or 7.2 above, the Administrator shall give notice in writing thereof to each Participant.

   

  	 	8.	PARTICIPATION SEPARATE FROM EMPLOYMENT OR SERVICE

   

  It shall be a condition of participation in the Plan that in the event of a Participant ceasing to be an employee or service provider (for whatever reason), he shall not, subject to any provision of applicable law to the contrary, be entitled to any compensation whatsoever by reason of any termination or alteration of rights or expectations under the Plan
    whether such compensation is claimed by way of damages for wrongful dismissal or breach of contract or for loss of office or otherwise howsoever. Participation in this Plan by a Participant is a matter entirely separate from any pension right or
    entitlement he may have and from his terms or conditions of employment or service and participation in this Plan shall in no respect whatever affect in any way a Participant’s pension rights or entitlement or terms or conditions of employment or
    service. As a condition to participation, each Participant acknowledges and agrees that the grant of an Award hereunder is in full satisfaction of the Service Recipient’s (or any affiliate of the Service Recipient) commitment to grant an equity-based
    award under an offer letter or other terms of employment or service. Any amounts paid or payable hereunder shall not constitute salary, wages or other remuneration or compensation, for purposes of any other
    benefit plan of any Service Recipient (or its affiliates).

   

  	 	9.	TAX AND SOCIAL SECURITY

   

  		9.1	The Participant is responsible for reporting the receipt of any income under the Plan, however made, to the appropriate tax authority in accordance with applicable law.

   

   

  
 9
  
    
      
 

  

  Payments made under this plan to Participants other than employees shall be deemed to be inclusive of VAT, if any.

   

  The grant, vesting or other relevant event of an Award will be subject to any withholding that may be necessary of or on account of a Participant’s tax
    liability and employee social security contribution liability in respect of that Award. The Company and the Service Recipient will be entitled to deduct or withhold a sufficient portion of the value otherwise due to be released to the Participant to
    satisfy any withholding liability. Without limitation, where withholding is required, withholding arrangements may include the sale of any Shares subject to an Award on behalf of a Participant and/or deductions from salary and/or bonus payments and/or
    fees, or require a payment from the Participant before settlement of the Award. If required in order to comply with any applicable laws, the Participant may be required to personally pay such sums as may be required for purposes of meeting the
    withholding obligations of the Company or the Service Recipient.

   

  The Company and the Service Recipient shall have the right to notify the tax authorities of the grant and payment of an Award and submit the tax
    authorities all documents in connection with the grant and payment of an Award, if so required by law.

   

  		9.2	The Company and the Service Recipient will be entitled to block or prohibit the release of a sufficient number of Shares otherwise due to be released or to offset any claims
          towards the Participant if the Participant has any outstanding obligations (whether in connection with the Plan or otherwise arising in the course of the Participant’s employment or service contract), until the Participant has satisfied such
          outstanding obligations.

   

  	 	10.	ADMINISTRATION, AMENDMENT AND TERMINATION

   

  		10.1	The Plan shall be interpreted and administered by the Administrator whose decision on all matters of interpretation and administration shall be final and
          binding on all parties.

   

  		10.2	There is no obligation for uniformity of treatment of Participants by the Administrators (either individually or collectively).

   

   

  
 10
  
    
      
 

  

  		10.3	Except with respect to Rules 2.3 and 2.4, the Administrator may from time to time make amendments to these Rules and the accompanying Country Annexes, provided that:

   

  		10.3.1	no amendment may detrimentally and materially affect a Participant as regards any Award held by him on the date of the amendment unless being made with the Participant’s
          consent, provided, however, that the foregoing restriction in this clause 10.3.1 shall not apply to any amendment required to comply with any applicable statute, regulation or enactment; and

   

  		10.3.2	written notice of any material alteration made in accordance with this Rule 10 shall be given to all affected Participants.

   

  		10.4	The Administrator may at any time resolve to terminate this Plan, in which event no further Awards shall be granted but the provisions of this Plan shall continue in force in
          relation to Awards subsisting prior to that date.

   

  		10.5	The Plan is intended to constitute an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant by the Service Recipient, nothing
          contained herein shall give any such Participant any rights that are greater than those of a general unsecured creditor of the Service Recipient. No trust fund shall be established for the payment or provision of benefits hereunder. The
          obligation to make payments under the Plan shall be contractual only and all such payments shall be made from the general assets of the Service Recipient.

   

  		10.6	Any notice to be given pursuant to the terms of these Rules must be given in writing to the party due to receive such notice at (in the case of the Company) its registered
          office address from time to time or (in the case of an individual) his address (including email address) as notified to the Company from time to time. Notice must be delivered personally or sent by post or electronic transmission and shall be
          deemed to be given in the case of personal delivery on delivery and in the case of posting (in the absence of evidence of earlier receipt) within 48 hours after posting (six days if sent by air mail) and in the case of electronic transmission two
          hours after sending.

   

   

  
 11
  
    
      
 

  

  		10.7	By accepting an Award, a Participant consents to the collection, holding, processing and transfer of the Participant’s Personal Data by any company in the Group for all
          purposes connected with the Awards, including

   

  		10.7.1	the transfer of the Participant’s Personal Data to the Company’s registrars or brokers or any administrators of the Company’s share incentive arrangements;
          and

   

  		10.7.2	the transfer of the Participant’s Personal Data to a prospective buyer of the Company or of any company in the Group or business unit which employs the
          Participant, and the prospective buyer’s professional advisers, provided that those persons irrevocably agree to use the Participant’s Personal Data only in connection with the proposed transaction and in accordance with the data protection
          principles set out in the relevant data protection legislation

        

   

   

  and, for the avoidance of doubt, any such permitted transfers shall include transfers of Personal Data to recipients located outside the EEA.

  

  

  		10.8	The Plan and its terms may be disclosed to (potential) investors in the Company or acquirers of the Company or all or parts of its assets, to underwriting
          banks, and in any prospectuses or other disclosure materials.

   

  		10.9	Except as otherwise provided in the Country Annex, the Rules and the Plan shall in all respects be governed by the laws of Switzerland.

   

  [Country Annexes Follow]

   

   

  
 12
  
    
      
 

  

  COUNTRY ANNEX FOR ADC THERAPEUTICS (UK) LIMITED  

  (“UK COMPANY”)

   

  The Rules governing awards to employees and service providers of the UK Company shall be as per the Plan, with the following differences:

   

  1.       Unless the Administrator determines otherwise in its discretion, Awards granted by the UK Company shall be granted over Notional Shares only,
    albeit that they may be satisfied in Shares on an IPO in accordance with Rule 6.3. The Plan, including in particular the definition of “Award” and Rule 3 shall be read accordingly.

   

  2.       The Administrator of the Plan shall be the UK Company. Under no circumstances shall payments be made under the Plan to UK-resident employees of
    the UK Company by any person other than the UK Company.

   

  COUNTRY ANNEX FOR ADC THERAPEUTICS AMERICA, INC.

  AND ANY U.S. TAXPAYER PARTICIPANTS

   

  The Rules governing awards to employees and service providers who are U.S. taxpayers subject to Section 409A of the U.S. Internal Revenue Code of 1986, as
    amended (together with regulations and published guidance thereunder, the “Code”) shall be as per the Plan, with the following differences:

   

  		1.	Awards hereunder are intended to constitute non-qualified stock options having a Strike Price no less than fair market value of a Share on the date of grant
          as determined under Code Section 409A, and those Awards shall be, subject to the terms of the Plan and this Annex, exercisable for Shares of the Company. All interpretations and determinations hereunder shall be made on a basis consistent with
          such intent. Any adjustment to an Award under Rule 7 shall be made in a manner intending to comply with Code Section 409A.

   

  		2.	The definition of “Award” means a right (for the time being subsisting) which following exercise (as applicable)

          and satisfaction of any strike price or, if earlier, a Liquidity Event will entitle the holder to receive Shares or a cash amount equal to the difference (if positive) between the Closing Value and the Strike Price, multiplied by the
          number of Vested Notional Shares or Shares subject to an Award.

   

   

  
 13
  
    
      
 

  

  	 	3.	The Plan is amended to add the following clause 6.4.3:

   

  		6.4.3	In each case above, no such payment shall be made to a Participant if such payment would result in adverse tax treatment under applicable law (including, without limitation,
          U.S. Internal Revenue Code Section 409A) or a material modification of such Award. Any such payment shall be made in a manner consistent with the intent that such Awards are intended to avoid such adverse tax treatment.

   

  		4.	This Plan is not a retirement or welfare benefit plan, and is not intended and shall not be construed to be a retirement or welfare benefit plan. Further,
          this Plan is not intended to defer the receipt of payments to the termination of a Participant’s employment or beyond, and shall not be governed by or subject to the federal Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

          All interpretations and determinations hereunder shall be made on a basis consistent with the Plan’s status as not an employee benefit plan subject to ERISA.

   

  		5.	Notwithstanding any other provision of this Plan, this Plan is intended to be exempt from Section 409A and Section 457A of the Code, and shall at all times
          be interpreted in accordance with such intent. In no event will the Company or its affiliates, or their members or affiliates, or their respective employees, directors, officers, agents, representatives, attorneys, equityholders, principals,
          members, managers or affiliates have any liability for any failure of the Plan to satisfy the requirements of, or be exempt from, Code Section 409A and/or Code Section 457A, and such parties do not guarantee that the Plan complies with, or is
          exempt from, Code Section 409A and/or Code Section 457A. No Participant shall have a binding right to distributions made to it in error. Each payment payable hereunder is and shall be deemed a payment in a series of separate payments for all
          purposes of Code Section 409A. All references to termination of service (and similar terms) shall mean a “separation from service” within the meaning of Treasury Regulation 1.409A-l(h).

   

  		6.	The terms of participation of any U.S. taxpayer in respect of his Award under the Plan will be set forth in an Award Letter, the terms of which shall
          control in the event of any inconsistency with the terms of the Plan.

   

  		7.	The right of a U.S. taxpayer Participant to exercise his Award and receive Shares shall be subject to the satisfaction of all requirements of applicable
          law concerning the Company, including, without limitation, obtaining board and shareholder approval to issue such Shares. In the event the Participant cannot, under applicable law, receive Shares upon exercise, then the Company can either (i)
          defer the Participant’s exercise to a time when delivery of Shares would not violate applicable law, or (ii) settle such Award in cash.

   

   

  
 14
  
    
      
 

  

  		8.	Any Shares delivered to a U.S. taxpayer Participant prior to a Liquidity Event shall be subject to a right of repurchase by the Company (or its
          affiliates), which may be assigned, as more fully set forth in an Award Letter.

   

  		9.	As a condition to the receipt of Shares following exercise of any option awarded under the Plan, a U.S. taxpayer Participant agrees to execute such
          documents as the Administrator shall, in its reasonable discretion, determine, including without limitation any lock-up agreement or shareholders’ agreement.

   

  		10.	In the event that any payment or benefit provided under the Plan would, based on the determination of counsel or the accountants for the Company, not be
          deemed to be deductible in whole or in part in the calculation of federal income tax of the Company, or any other person making such payment, by reason of Section 280G of the Code or result in the imposition of taxes under Code Section 4999 to
          the Participant, the aggregate payments, coverages or benefits provided under the Plan and any other arrangement on account of a “change in control” shall be reduced to one dollar less than the “safe harbor” level under Section 280G so that the
          entire amount that is paid or provided to the Participant shall be deductible notwithstanding the provisions of Section 280G of the Code; provided, however, that the Company agrees to use commercially reasonable efforts to obtain
          shareholder approval of any payments or benefits in excess of the safe harbor level in accordance with Q&A #7 of Section 280G of the Code so that there will be no such loss of deductibility under Section 280G or imposition of tax under
          Section 4999, and in connection with such efforts to obtain shareholder approval, Plan Participants agree to waive any amounts in excess of such safe harbor level. All determinations regarding the manner of cutback shall be reasonably determined
          by the Plan Administrator in a manner that does not violate Section 409A of the Code, as applicable.

   

  
    
 

  15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]